Clinical features of polymyalgia rheumatica and giant cell arteritis

Nature Reviews Rheumatology

Volumn 8, Issue 9, 2012, Pages 509-521

  Salvarani, Carlo ^a   Pipitone, Nicolò ^a   Versari, Annibale ^a   Hunder, Gene G ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CD86 ANTIGEN; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; GLUCOCORTICOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 32; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PREDNISONE; TOCILIZUMAB; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN;

AMYLOIDOSIS; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ARTHRALGIA; BACTERIAL ENDOCARDITIS; BLOOD VESSEL BIOPSY; BRAIN VASCULITIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; CRITERION VARIABLE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; GENE MUTATION; GENETIC ASSOCIATION; GIANT CELL ARTERITIS; HEADACHE; HEMATOLOGIC MALIGNANCY; HEREDITY; HUMAN; IMAGE ANALYSIS; INCIDENCE; INFLAMMATION; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MORNING STIFFNESS; MORTALITY; OPHTHALMOSCOPY; OSTEOPOROSIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; SYMPTOMATOLOGY; TEMPORAL ARTERY; UNSPECIFIED SIDE EFFECT; VASCULITIS; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

AGED, 80 AND OVER; BIOPSY; COMORBIDITY; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; TEMPORAL ARTERIES;

EID: 84866096209     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.97     Document Type: Review

References (148)

1. Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261-271 (2002
2. Gonzalez-Gay, M. A. et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 61, 1454-1461 (2009)
3. Smith, C. A., Fidler, W. J. & Pinals, R. S. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 26, 1214-1219 (1983
4. Pereira, L. S. et al. Giant cell arteritis in Asians: A comparative study. Br. J. Ophthalmol. 95, 214-216 (2011
5. Salvarani, C., Cantini, F. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 372, 234-245 (2008
6. Pipitone, N., Boiardi, L., Bajocchi, G. & Salvarani, C. Long-term outcome of giant cell arteritis. Clin. Exp. Rheumatol. 24, S65-S70 (2006
7. Gran, J. T., Myklebust, G., Wilsgaard, T. & Jacobsen, B. K. Survival in polymyalgia rheumatica and temporal arteritis: A study of 398 cases and matched population controls. Rheumatology (Oxford) 40, 1238-1242 (2001
8. Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J., McClelland, R. L. & Matteson, E. L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum. 48, 3532-3537 (2003
9. Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 33, 1122-1128 (1990
10. Karahaliou, M. et al. Colour duplex sonography of temporal arteries before decision for biopsy: A prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res. Ther. 8, R116 (2006
11. Dasgupta, B. et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum Dis. 71, 484-492 (2012
12. Salvarani, C., Gabriel, S. E., O'Fallon, W. M. & Hunder, G. G. The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern. Ann. Intern. Med. 123, 192-194 (1995
13. Weyand, C. M. et al. Vascular dendritic cells in giant cell arteritis. Ann. NY Acad. Sci. 1062, 195-208 (2005
14. Pipitone, N. & Salvarani, C. The role of infectious agents in the pathogenesis of vasculitis. Best Pract. Res. Clin. Rheumatol. 22, 897-911 (2008
15. Gonzalez-Gay, M. A., Garcia-Porrua, C. & Ollier, W. E. Polymyalgia rheumatica and biopsy-proven giant cell arteritis exhibit different HLA-DRB1. associations. J. Rheumatol. 30, 2729 (2003
16. Gonzalez-Gay, M. A., Amoli, M. M., Garcia-Porrua, C. & Ollier, W. E. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum. 33, 38-48 (2003
17. Gonzalez-Gay, M. A. et al. IL6 promoter polymorphism at position 174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin. Exp. Rheumatol. 20, 179-184 (2002
18. Salvarani, C. et al. Interleukin 6 promoter polymorphism at position -174 in giant cell arteritis. J. Rheumatol. 32, 2173-2177 (2005
19. Gonzalez-Gay, M. A. et al. Contribution of MHC class I region to genetic susceptibility for giant cell arteritis. Rheumatology (Oxford) 46, 431-434 (2007
20. Enjuanes, A. et al. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA - a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology (Oxford) 51, 841-851 (2012
21. Salvarani, C. et al. PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 56, 3502-3508 (2007
22. Esteban, M. J. et al. Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum. 44, 1387-1395 (2001
23. Restuccia, G. et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. Arthritis Rheum. 64, 549-556 (2012
24. Makkuni, D. et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 47, 488-490 (2008
25. Han, J. W. et al. Vessel wall-embedded dendritic cells induce T cell autoreactivity and initiate vascular inflammation. Circ. Res. 102, 546-553 (2008
26. Weyand, C. M. & Goronzy, J. J. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 42, 844-853 (1999
27. Pryshchep, O., Ma-Krupa, W., Younge, B. R., Goronzy, J. J. & Weyand, C. M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118, 1276-1284 (2008
28. Deng, J., Younge, B. R., Olshen, R. A., Goronzy, J. J. & Weyand, C. M. TH17 and TH1 T cell responses in giant cell arteritis. Circulation 121, 906-915 (2010
29. Ciccia, F. et al. Expression of interleukin 32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 63, 2097-2104 (2011
30. Terrier, B. et al. IL 21 modulates TH1 and TH17 responses in giant cell arteritis. Arthritis Rheum. 64, 2001-2011 (2012
31. Visvanathan, S. et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis - A prospective longitudinal study. Rheumatology (Oxford) 50, 2061-2070 (2011
32. Kaiser, M., Weyand, C. M., Bjornsson, J. & Goronzy, J. J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 41, 623-633 (1998
33. Lozano, E., Segarra, M., Garcia-Martinez, A., Hernandez-Rodriguez, J. & Cid, M. C. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann. Rheum Dis. 67, 1581-1588 (2008
34. Kaiser, M., Younge, B., Bjornsson, J., Goronzy, J. J. & Weyand, C. M. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am. J. Pathol. 155, 765-774 (1999
35. Wagner, A. D., Goronzy, J. J. & Weyand, C. M. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J. Clin. Invest 94, 1134-1140 (1994
36. Hernandez-Rodriguez, J. et al. Tissue production of pro-inflammatory cytokines (IL 1β, TNF-α and IL 6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43, 294-301 (2004
37. Field, M., Cook, A. & Gallagher, G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol. Int. 17, 113-118 (1997
38. Hernandez-Rodriguez, J. et al. Elevated production of interleukin 6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin 6 as a potential protective mechanism. Circulation 107, 2428-2434 (2003
39. Segarra, M. et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann. Rheum. Dis. 66, 1429-1435 (2007
40. Rodriguez-Pla, A. et al. Metalloproteinase 2 and 9 in giant cell arteritis: Involvement in vascular remodeling. Circulation 112, 264-269 (2005
41. Machado, E. B. et al. A population-based case-control study of temporal arteritis: Evidence for an association between temporal arteritis and degenerative vascular disease? Int. J. Epidemiol. 18, 836-841 (1989
42. Duhaut, P. et al. Anticardiolipin antibodies and giant cell arteritis: A prospective, multicenter case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum. 41, 701-709 (1998
43. Gonzalez-Gay, M. A. et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 83, 342-347 (2004
44. Weyand, C. M., Hicok, K. C., Hunder, G. G. & Goronzy, J. J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann. Intern. Med. 121, 484-491 (1994
45. Kreiner, F., Langberg, H. & Galbo, H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 62, 3768-3775 (2010
46. Kreiner, F. & Galbo, H. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica. Pain 152, 1127-1132 (2011
47. Paraskevas, K. I., Boumpas, D. T., Vrentzos, G. E. & Mikhailidis, D. P. Oral and ocular/orbital manifestations of temporal arteritis: A disease with deceptive clinical symptoms and devastating consequences. Clin. Rheumatol. 26, 1044-1048 (2007
48. Hayreh, S. S., Podhajsky, P. A. & Zimmerman, B. Ocular manifestations of giant cell arteritis. Am. J. Ophthalmol. 125, 509-520 (1998
49. Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48, 250-253 (2009
50. Hernandez-Rodriguez, J. et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 47, 29-35 (2002
51. Salvarani, C. et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 53, 293-297 (2005
52. Gonzalez-Gay, M. A. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41, 1497-1504 (1998
53. Ezeonyeji, A. N., Borg, F. A. & Dasgupta, B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin. Rheumatol. 30, 259-262 (2011
54. Calamia, K. T. & Hunder, G. G. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 24, 1414-1418 (1981
55. Olopade, C. O., Sekosan, M. & Schraufnagel, D. E. Giant cell arteritis manifesting as chronic cough and fever of unknown origin. Mayo Clin. Proc. 72, 1048-1050 (1997
56. Brack, A., Martinez-Taboada, V., Stanson, A., Goronzy, J. J. & Weyand, C. M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 42, 311-317 (1999
57. Nuenninghoff, D. M., Hunder, G. G., Christianson, T. J., McClelland, R. L. & Matteson, E. L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum. 48, 3522-3531 (2003
58. Bongartz, T. & Matteson, E. L. Large-vessel involvement in giant cell arteritis. Curr. Opin. Rheumatol. 18, 10-17 (2006
59. Blockmans, D. et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47, 1179-1184 (2008
60. Garcia-Martinez, A. et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 59, 422-430 (2008
61. Stone, J. H. Vasculitis: A collection of pearls and myths. Rheum. Dis. Clin. North Am. 33, 691-739 (2007
62. Salvarani, C. et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. Arthritis Rheum. 41, 1221-1226 (1998
63. Hunder, G. G. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin. Proc. 81, 1071-1083 (2006
64. Gonzalez-Gay, M. A., Garcia-Porrua, C., Amor-Dorado, J. C. & Llorca, J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum. 51, 274-277 (2004
65. Blockmans, D. et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: A prospective study in 35 patients. Rheumatology (Oxford) 46, 672-677 (2007
66. Hernandez-Rodriguez, J. et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Medicine (Baltimore) 86, 233-241 (2007
67. Eshaghian, J. & Goeken, J. A. Creactive protein in giant cell (cranial, temporal) arteritis. Ophthalmology 87, 1160-1166 (1980
68. Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin. Exp. Rheumatol. 21, S23-S28 (2003
69. Kyle, V., Cawston, T. E. & Hazleman, B. L. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann. Rheum. Dis. 48, 667-671 (1989
70. Kyle, V., Wraight, E. P. & Hazleman, B. L. Liver scan abnormalities in polymyalgia rheumatica/giant cell arteritis. Clin. Rheumatol. 10, 294-297 (1991
71. Klein, R. G., Campbell, R. J., Hunder, G. G. & Carney, J. A. Skip lesions in temporal arteritis. Mayo Clin. Proc. 51, 504-510 (1976
72. Germano, G. et al. Does ultrasonography guidance increase the yield of temporal artery biopsy in patients with giant cell arteritis? Preliminary results from a single-blinded randomized study. Arthritis & Rheumatism 63, S594 (2011
73. Salvarani, C. & Hunder, G. G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum. 45, 140-145 (2001
74. Narvaez, J. et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin. Arthritis Rheum. 37, 13-19 (2007
75. Breuer, G. S., Nesher, G. & Nesher, R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J. Rheumatol. 36, 794-796 (2009
76. Rucker, J. C., Biousse, V. & Newman, N. J. Ischemic optic neuropathies. Curr. Opin. Neurol. 17, 27-35 (2004
77. Pipitone, N., Versari, A. & Salvarani, C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: An update. Rheumatology (Oxford) 47, 403-408 (2008
78. Salvarani, C. et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann. Intern. Med. 137, 232-238 (2002
79. Schmidt, W. A., Kraft, H. E., Vorpahl, K., Volker, L. & Gromnica-Ihle, E J. Color duplex ultrasonography in the diagnosis of temporal arteritis. N. Engl. J. Med. 337, 1336-1342 (1997
80. Ball, E. L., Walsh, S. R., Tang, T. Y., Gohil, R. & Clarke, J. M. Role of ultrasonography in the diagnosis of temporal arteritis. Br. J. Surg. 97, 1765-1771 (2010
81. Arida, A., Kyprianou, M., Kanakis, M. & Sfikakis, P. P. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: A second meta-analysis. BMC Musculoskelet. Disord. 11, 44 (2010
82. Bley, T. A. et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum. 52, 2470-2477 (2005
83. Walter, M. A. et al. The value of 18FFDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nucl. Med. Mol. Imaging 32, 674-681 (2005
84. Blockmans, D. et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 55, 131-137 (2006
85. Cantini, F. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: A case-control study. J. Rheumatol. 28, 1049-1055 (2001
86. Salvarani, C. et al. Proximal bursitis in active polymyalgia rheumatica. Ann. Intern. Med. 127, 27-31 (1997
87. Salvarani, C. et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann. Rheum. Dis. 67, 758-761 (2008
88. Camellino, D. & Cimmino, M. A. Imaging of polymyalgia rheumatica: Indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 51, 77-86 (2011
89. Cantini, F. et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum. 44, 1155-1159 (2001
90. Cantini, F. et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J. Rheumatol. 31, 120-124 (2004
91. Cimmino, M. A., Parodi, M., Zampogna, G., Barbieri, F. & Garlaschi, G. Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: A magnetic resonance imaging study. Rheumatology (Oxford) 50, 494-499 (2011
92. Nishino, H., DeRemee, R. A., Rubino, F. A. & Parisi, J. E. Wegener's granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin. Proc. 68, 115-121 (1993
93. Salvarani, C. et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 37, 1621-1626 (1994
94. Genereau, T. et al. Temporal artery biopsy: A diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 42, 2674-2681 (1999
95. Salvarani, C., Giannini, C., Miller, D. V. & Hunder, G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum. 55, 985-989 (2006
96. Deal, C. L. et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis & Rheumatism 28, 987-994 (1985
97. Lopez-Hoyos, M. et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 43, 655-657 (2004
98. Olivieri, I., Salvarani, C. & Cantini, F. Remitting distal extremity swelling with pitting edema: A distinct syndrome or a clinical feature of different inflammatory rheumatic diseases? J. Rheumatol. 24, 249-252 (1997
99. Olivieri, I. et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: Description of seven cases. Rheumatol. Int. 27, 927-933 (2007
100. Salvarani, C., Cantini, F., Oliveri, I. & Hunder, G. G. Polymyalgia rheumatica: A disorder of extraarticular synovial structures. J. Rheumatol. 26, 517-521 (1999
101. Churchill, M. A., Jr, Geraci, J. E. & Hunder, G. G. Musculoskeletal manifestations of bacterial endocarditis. Ann. Intern. Med 87, 754-759 (1977
102. Pipitone, N. & Salvarani, C. Improving therapeutic options for patients with giant cell arteritis. Curr. Opin. Rheumatol. 20, 17-22 (2008
103. Sailler, L. et al. Non-complicated Horton's disease: Initial treatment with methylprednisolone 500 mg/day bolus for three days followed by 20 mg/day prednisone-equivalent. Evaluation of 15 patients [French]. Rev. Med. Interne 22, 1032-1038 (2001
104. Chevalet, P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J. Rheumatol. 27, 1484-1491 (2000
105. Hayreh, S. S. & Zimmerman, B. Management of giant cell arteritis. Our 27-year clinical study: New light on old controversies. Ophthalmologica 217, 239-259 (2003
106. Kyle, V. & Hazleman, B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann. Rheum. Dis. 48, 658-661 (1989
107. Delecoeuillerie, G., Joly, P., Cohen, D. L. & Paolaggi, J. B. Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann. Rheum. Dis. 47, 733-739 (1988
108. Hunder, G. G., Sheps, S. G., Allen, G. L. & Joyce, J. W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann. Intern. Med. 82, 613-618 (1975
109. Mukhtyar, C. et al. EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 68, 318-323 (2009
110. Mazlumzadeh, M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310-3318 (2006
111. Dasgupta, B. et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. (Oxford) 49, 1594-1597 (2010
112. Pipitone, N., Boiardi, L. & Salvarani, C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best. Pract. Res. Clin. Rheumatol. 19, 277-292 (2005
113. Huston, K. A., Hunder, G. G., Lie, J. T., Kennedy, R. H. & Elveback, L. R. Temporal arteritis: A 25-year epidemiologic, clinical, and pathologic study. Ann. Intern. Med. 88, 162-167 (1978
114. Lundberg, I. & Hedfors, E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J. Rheumatol. 17, 1340-1345 (1990
115. Graham, E., Holland, A., Avery, A. & Russell, R. W. Prognosis in giant-cell arteritis. Br. Med. J. (Clin. Res. Ed) 282, 269-271 (1981
116. Hayreh, S. S. & Zimmerman, B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110, 1204-1215 (2003
117. Ostor, A. J. & Hazleman, B. L. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 2083-2085 (2002
118. Kyle, V. & Hazelman, B. L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 300, 344-345 (1990
119. Dasgupta, B. et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49, 186-190 (2010
120. Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M. & Hunder, G. G. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum. 49, 703-708 (2003
121. Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M. & Hunder, G. G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 40, 1873-1878 (1997
122. De Silva, M. & Hazleman, B. L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double-blind study. Ann. Rheum. Dis. 45, 136-138 (1986
123. Spiera, R. F. et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin. Exp. Rheumatol. 19, 495-501 (2001
124. Jover, J. A. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134, 106-114 (2001
125. Hoffman, G. S. et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46, 1309-1318 (2002
126. Mahr, A. D. et al. Adjunctive methotrexate to treat giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 56, 2789-2797 (2007
127. van der Veen, M. J., Dinant, H. J., Booma-Frankfort, C., Albada-Kuipers, G. A. & Bijlsma, J. W. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann. Rheum. Dis. 55, 218-223 (1996
128. Caporali, R. et al. Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 141, 493-500 (2004
129. Hoffman, G. S. et al. Infliximab for maintenance of glucocorticosteroid- induced remission of giant cell arteritis: A randomized trial. Ann. Intern. Med. 146, 621-630 (2007
130. Salvarani, C. et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: A randomized trial. Ann. Intern. Med. 146, 631-639 (2007
131. Kreiner, F. & Galbo, H. Effect of etanercept in polymyalgia rheumatica: A randomized controlled trial. Arthritis Res. Ther. 12, R176 (2010
132. Martinez-Taboada, V. M. et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67, 625-630 (2008
133. Salvarani, C. et al. Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study. J. Rheumatol. 30, 760-763 (2003
134. Cantini, F., Niccoli, L., Salvarani, C., Padula, A. & Olivieri, I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 44, 2933-2935 (2001
135. Watson, P. & Gaston, H. Response to 'Effect of etanercept in polymyalgia rheumatica: A randomized controlled trial'. Arthritis Res. Ther. 13, 403 (2011
136. Seitz, M. et al. Rapid induction of remission in large vessel vasculitis by IL6 blockade. A case series. Swiss. Med. Wkly 141, w13156 (2011
137. Salvarani, C. et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 51, 151-156 (2012
138. Hagihara, K., Kawase, I., Tanaka, T. & Kishimoto, T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol. 37, 1075-1076 (2010
139. Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332-1337 (2004
140. Lee, M. S., Smith, S. D., Galor, A. & Hoffman, G. S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 54, 3306-3309 (2006
141. Narvaez, J. et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin. Exp. Rheumatol. 26, S57-S62 (2008
142. Leeb, B. F. et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann. Rheum. Dis. 62, 1189-1194 (2003
143. Leeb, B. F. & Bird, H. A. A disease activity score for polymyalgia rheumatica. Ann. Rheum Dis. 63, 1279-1283 (2004
144. Matteson, E. L. et al. Patient-reported outcomes in polymyalgia rheumatica. J. Rheumatol. 39, 795-803 (2012
145. Chuang, T. Y., Hunder, G. G., Ilstrup, D. M. & Kurland, L. T. Polymyalgia rheumatica: A 10-year epidemiologic and clinical study. Ann. Intern. Med. 97, 672-680 (1982
146. Healey, L. A. Long-term follow-up of polymyalgia rheumatica: Evidence for synovitis. Semin. Arthritis Rheum. 13, 322-328 (1984
147. Bird, H. A., Esselinckx, W., Dixon, A. S., Mowat, A. G. & Wood, P. H. An evaluation of criteria for polymyalgia rheumatica. Ann. Rheum. Dis. 38, 434-439 (1979
148. Michet, C. J. & Matteson, E. L. Polymyalgia rheumatica. BMJ 336, 765-769 (2008)